Novo seeks to REPAIR funding in antibiotics companies

In response to an expanding funding gap for antimicrobial resistance companies, Novo Holdings is expanding the remit of its early stage REPAIR Impact Fund to include investments as late as Phase II for the fund’s portfolio companies.

Novo Holdings A/S launched the fund in 2018 with $165 million to invest over three to five years in start-ups, early-stage companies and corporate spinouts focused on programs targeting high-priority pathogens. The fund’s focus was investing in compounds in the “valley of death” between lead optimization and Phase I testing...